Anlon Healthcare Ltd
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).[1]
- Market Cap ₹ 724 Cr.
- Current Price ₹ 13.6
- High / Low ₹ 17.3 / 8.70
- Stock P/E 26.0
- Book Value ₹ 3.95
- Dividend Yield 0.00 %
- ROCE 22.4 %
- ROE 19.2 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is expected to give good quarter
- Company has delivered good profit growth of 36.4% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.6%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 215 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 16 | 57 | 113 | 66 | 120 | 176 | |
| 21 | 52 | 100 | 51 | 88 | 130 | |
| Operating Profit | -5 | 6 | 13 | 16 | 33 | 46 |
| OPM % | -32% | 10% | 11% | 24% | 27% | 26% |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 3 | 4 | 4 | 4 | 4 | 4 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 1 |
| Profit before tax | -10 | -0 | 7 | 10 | 27 | 41 |
| Tax % | 3% | 0% | 17% | 1% | 24% | 32% |
| -10 | -0 | 6 | 10 | 21 | 28 | |
| EPS in Rs | -0.85 | -0.01 | 0.48 | 0.60 | 0.51 | 0.52 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 62% |
| 3 Years: | 16% |
| TTM: | 47% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | 68% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 28% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 16 | 40 | 53 |
| Reserves | -10 | -10 | -5 | 5 | 41 | 157 |
| 54 | 62 | 70 | 81 | 67 | 46 | |
| 16 | 21 | 34 | 26 | 34 | 62 | |
| Total Liabilities | 71 | 85 | 112 | 128 | 181 | 317 |
| 29 | 27 | 26 | 27 | 23 | 40 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 2 | 4 | 1 | 1 | 10 |
| 43 | 56 | 82 | 100 | 158 | 267 | |
| Total Assets | 71 | 85 | 112 | 128 | 181 | 317 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| -15 | -2 | -3 | -3 | -23 | ||
| -2 | -0 | -0 | -3 | 3 | ||
| 16 | 3 | 2 | 8 | 19 | ||
| Net Cash Flow | -2 | 1 | -1 | 2 | -1 | |
| Free Cash Flow | -15 | -2 | -3 | -7 | -20 | |
| CFO/OP | 291% | -32% | -23% | -21% | -66% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 132 | 130 | 142 | 213 | 228 | 215 |
| Inventory Days | 669 | 225 | 112 | 452 | 246 | 245 |
| Days Payable | 409 | 128 | 105 | 217 | 96 | 128 |
| Cash Conversion Cycle | 392 | 226 | 149 | 448 | 377 | 332 |
| Working Capital Days | 185 | 163 | 122 | 261 | 292 | 321 |
| ROCE % | 7% | 15% | 15% | 25% | 22% |
Insights
In beta| Mar 2018 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Total Commercialized Products Number |
|
|||
| Actual Production Volume MT |
||||
| Capacity Utilization % |
||||
| Export Contribution to Revenue % |
||||
| Installed Production Capacity MTPA |
||||
| Products in R&D Pipeline (Pilot/Lab) Number |
||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Copy of newspaper publication dated May 30, 2026 regarding publication of extract of Audited Financial Results (Standalone and Consolidated) for Quarter and Year ended 31st …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
30 May - Audited Q4/FY26 results: consolidated income ₹172.22 Cr, PAT ₹29.09 Cr; Bizotic Lifescience acquired.
- Considered, Approved And Taken On Record Audited Financial Results For The Quarter And Year Ended 31St March, 2026 29 May
-
Board Meeting Outcome for To Consider And Approve Financial Results For The Quarter And Year Ended March 31, 2026
29 May - Board approved FY26 audited standalone and consolidated results; auditor issued unmodified opinion.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 May
Concalls
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
Business Profile[1]
Anlon Healthcare is a chemical manufacturing company engaged in:
a) Pharmaceutical Intermediates – high-purity intermediates used as raw material/starting material in APIs.
b) Active Pharmaceutical Ingredients (APIs) – raw material for finished dosage formulations (tablets, capsules, ointments, syrups, etc.), nutraceuticals, personal care, and veterinary products.
c) It recently expanded into custom manufacturing services for complex/novel chemical compounds, including high-purity chemicals.